Analysts Offer Predictions for NeuroPace FY2026 Earnings

NeuroPace, Inc. (NASDAQ:NPCE) – Analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for NeuroPace in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst R. Osborn anticipates that the company will post earnings per share of ($0.61) for the year. Cantor Fitzgerald has a “Overweight” rating and a $17.00 price objective on the stock. The consensus estimate for NeuroPace’s current full-year earnings is ($1.00) per share.

Other equities analysts have also issued research reports about the stock. HC Wainwright initiated coverage on shares of NeuroPace in a report on Wednesday, May 28th. They issued a “buy” rating and a $18.00 price objective on the stock. JPMorgan Chase & Co. upped their target price on shares of NeuroPace from $14.00 to $16.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 14th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $15.50.

NeuroPace Price Performance

Shares of NASDAQ NPCE opened at $12.93 on Tuesday. The company has a debt-to-equity ratio of 6.03, a current ratio of 5.59 and a quick ratio of 4.77. The firm has a market capitalization of $424.09 million, a PE ratio of -12.93 and a beta of 2.03. NeuroPace has a 1-year low of $5.45 and a 1-year high of $18.98. The business’s fifty day moving average price is $12.90 and its two-hundred day moving average price is $12.37.

NeuroPace (NASDAQ:NPCE) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.05. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%. The business had revenue of $22.52 million for the quarter, compared to the consensus estimate of $21.85 million.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of NPCE. BNP Paribas Financial Markets acquired a new stake in shares of NeuroPace in the 4th quarter valued at $29,000. GAMMA Investing LLC bought a new position in NeuroPace during the first quarter valued at about $53,000. Wells Fargo & Company MN raised its stake in shares of NeuroPace by 54.2% in the 4th quarter. Wells Fargo & Company MN now owns 6,483 shares of the company’s stock valued at $73,000 after acquiring an additional 2,279 shares in the last quarter. MetLife Investment Management LLC bought a new position in shares of NeuroPace in the fourth quarter valued at approximately $103,000. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of NeuroPace during the 4th quarter worth $112,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

Insider Activity

In other NeuroPace news, major shareholder Orbimed Advisors Llc sold 168,136 shares of NeuroPace stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $15.85, for a total value of $2,664,955.60. Following the completion of the sale, the insider now directly owns 3,238,199 shares in the company, valued at $51,325,454.15. The trade was a 4.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 22.20% of the stock is currently owned by corporate insiders.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.